• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Valeritas touts new data for insulin delivery device

May 18, 2018 By Sarah Faulkner

Valeritas V-Go deviceValeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes.

In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens.

“Poor glycemic control (A1C above 9.0%) places patients at high risk for long-term complications and negatively impacts health care costs. Exploring new treatment options which translate into improved glycemic control can benefit patients and have positive implications for health care costs and utilization,” lead author Dr. Patricia Wu said in prepared remarks.

“In our study, use of V-Go resulted in significant improvement in glycemic control and reduced the percentage of patients poorly controlled and at high risk. Diabetes management can be challenging, and the improvements seen in this study are encouraging and clinically relevant,” she added.

In a second presentation, Valeritas presented work from a prospective pilot study that used continuous glucose monitoring to compare time spent in-range for patients taking three or more insulin injection per day versus time spent in-range after switching to V-Go.

““Understanding the percent of time a patient is within an established blood glucose range is an important measure when evaluating glycemic control,” lead author Dr. Shreya Parikh said. “The goal is always to improve blood glucose time in range without increasing hypoglycemia, and I am pleased to see switching to V-Go for insulin delivery achieved this goal and was preferred by patients over their prior insulin regimens.”

After switching to V-Go, the average time spent in-range for patients climbed by 35%, according to Valeritas, compared to baseline insulin therapy. Six out of seven patients had improved time-in-range measures and in those six patients, the average time spent in-range increased by 49%. Those six patients also saw their insulin use drop from 83 units per day to 56 units per day, on average.

The company’s research was presented at the American Association of Clinical Endocrinologists Annual Scientific & Clinical Congress in Boston, Mass.

“We are excited by the results of these two new studies,” president & CEO John Timberlake said in prepared remarks. “The simple, convenient manner in which V-Go delivers basal-bolus therapy continues to prove clinically beneficial and is patient preferred.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Valeritas Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Reader Interactions

Comments

  1. Mary says

    May 22, 2018 at 1:54 pm

    Your article states “Type II Diabetes”
    Roman numerals have not been used for about 10 years when referring to the types of diabetes.

    Recommend using type 1 diabetes (T1D) or type 2 diabetes (T2D)

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS